
Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Your AI-Trained Oncology Knowledge Connection!


Jin-Ji Yang, MD is an oncologist at Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, at the Guangdong Academy of Medical Sciences at the Southern Medical University.

Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.